mTOR抑制剂使用的实际考量
Practical considerations for the use of mTOR inhibitors.
作者信息
Diekmann Fritz, Campistol Josep M
机构信息
Department of Nephrology and Kidney Transplantation, Hospital Clínic, Villarroel, 170, E-08036 Barcelona, Spain ; Servicio de Nefrología - Clinical Institute of Nephrology and Urology, Hospital Clinic, Barcelona, Spain.
Department of Nephrology and Kidney Transplantation, Hospital Clínic, Villarroel, 170, E-08036 Barcelona, Spain.
出版信息
Transplant Res. 2015 Dec 22;4(Suppl 1):5. doi: 10.1186/s13737-015-0029-5. eCollection 2015.
Abstract
Immunosuppressive therapy after kidney transplantation is based on calcineurin inhibitors (CNI). In most cases CNI therapy is combined with mycophenolate and steroids. In spite of good short-term results this therapy is associated with long-term toxicities, graft loss and patient death. Therefore, alternative immunosuppressive strategies are needed that combine excellent efficacy with low incidences of long-term adverse outcomes. This review focuses on the strategies based on mTOR- inhibitors in combination with minimized exposure to CNI.
摘要
肾移植后的免疫抑制治疗以钙调神经磷酸酶抑制剂（CNI）为基础。在大多数情况下，CNI治疗与霉酚酸酯和类固醇联合使用。尽管短期效果良好，但这种治疗与长期毒性、移植肾丢失和患者死亡有关。因此，需要替代的免疫抑制策略，将卓越的疗效与低发生率的长期不良后果相结合。本综述重点关注基于mTOR抑制剂并尽量减少CNI暴露的策略。
相似文献
1
Practical considerations for the use of mTOR inhibitors.mTOR抑制剂使用的实际考量
Transplant Res. 2015 Dec 22;4(Suppl 1):5. doi: 10.1186/s13737-015-0029-5. eCollection 2015.
2
Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.儿童实体器官移植受者中钙调神经磷酸酶抑制剂诱导的肾毒性的治疗策略。
Pediatr Transplant. 2006 Sep;10(6):721-9. doi: 10.1111/j.1399-3046.2006.00577.x.
3
Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.肾移植中减少类固醇和钙调神经磷酸酶抑制剂的方案
Transplant Proc. 2011 Mar;43(2):472-7. doi: 10.1016/j.transproceed.2011.01.054.
4
Immunosuppressive minimization with mTOR inhibitors and belatacept.使用mTOR抑制剂和贝拉西普实现免疫抑制最小化。
Transpl Int. 2015 Aug;28(8):921-7. doi: 10.1111/tri.12603. Epub 2015 Jun 8.
5
Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.实体器官移植中减少钙调神经磷酸酶抑制剂的方案：关注改善肾功能和肾毒性。
Clin Transplant. 2008 Jan-Feb;22(1):1-15. doi: 10.1111/j.1399-0012.2007.00739.x.
6
Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.关注肾移植中的mTOR抑制剂和他克莫司：药代动力学、暴露-反应关系及临床结局。
Transpl Immunol. 2014 Jun;31(1):22-32. doi: 10.1016/j.trim.2014.05.002. Epub 2014 May 24.
7
An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.基于mTOR抑制剂的方案及心脏死亡后供体肾移植受者的无钙调神经磷酸酶抑制剂（CNI）治疗：肾功能良好，但转换为CNI的发生率高。
Transpl Int. 2016 Mar;29(3):362-8. doi: 10.1111/tri.12732.
8
Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience.肾移植受者从钙调磷酸酶抑制剂转换为 mTOR 抑制剂的 4 年分析结果：单中心经验。
Ren Fail. 2011;33(8):789-94. doi: 10.3109/0886022X.2011.601826. Epub 2011 Jul 25.
9
Long-term maintenance therapy with calcineurin inhibitors: an update.钙调神经磷酸酶抑制剂的长期维持治疗：最新进展
Transplant Proc. 2010 Nov;42(9 Suppl):S21-4. doi: 10.1016/j.transproceed.2010.09.015.
10
Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
Transpl Int. 2004 Jul;17(6):279-85. doi: 10.1007/s00147-004-0716-5. Epub 2004 Jun 22.
引用本文的文献
1
Frequency and Outcomes of Acute Kidney Injury in the First Month Post-transplant: A Study on Renal Transplant Recipients in a Resource-Limited Country.肾移植后首个月急性肾损伤的发生率及结局：对资源有限国家肾移植受者的一项研究
Cureus. 2025 Mar 9;17(3):e80277. doi: 10.7759/cureus.80277. eCollection 2025 Mar.
2
The Evaluation and Management of Coronary Artery Disease in the Lung Transplant Patient.肺移植患者冠状动脉疾病的评估与管理
J Clin Med. 2023 Dec 13;12(24):7644. doi: 10.3390/jcm12247644.
3
Calcineurin and mTOR inhibitors in kidney transplantation: integrative metamodeling on transplant survival and kidney function.肾移植中的钙调神经磷酸酶抑制剂和雷帕霉素靶蛋白抑制剂：关于移植存活和肾功能的整合元建模
Int Urol Nephrol. 2024 Apr;56(4):1403-1414. doi: 10.1007/s11255-023-03754-3. Epub 2023 Sep 26.
4
High Dimensional Renal Profiling: Towards a Better Understanding or Renal Transplant Immune Suppression.高维肾脏分析：迈向对肾移植免疫抑制的更好理解
Curr Transplant Rep. 2019 Mar;6(1):60-68. doi: 10.1007/s40472-019-0225-1. Epub 2019 Jan 14.
5
Proceedings of the 13th international transplantation symposia: mTOR-inhibition: what have we learned and how so we best apply the learning.第13届国际移植研讨会会议记录：mTOR抑制：我们学到了什么以及如何最好地应用所学知识。
Transplant Res. 2015 Dec 22;4(Suppl 1):4. doi: 10.1186/s13737-015-0027-7. eCollection 2015.
本文引用的文献
1
Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.肾移植患者从环孢素转换为依维莫司的五年结局：随机ZEUS研究
Am J Transplant. 2015 Jan;15(1):119-28. doi: 10.1111/ajt.12952. Epub 2014 Dec 17.
2
Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation.移植后 mTOR 抑制剂联合治疗与他克莫司最小化的回顾。
Transplant Rev (Orlando). 2013 Oct;27(4):97-107. doi: 10.1016/j.trre.2013.06.001. Epub 2013 Aug 8.
3
Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation.早期从钙调磷酸酶抑制剂转换为依维莫司可改善肾功能：肾移植中的一项随机试验。
Am J Transplant. 2012 Oct;12(10):2744-53. doi: 10.1111/j.1600-6143.2012.04162.x. Epub 2012 Jul 19.
4
Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study.随机试验比较肾移植中雷帕霉素和环孢素的 5 年结果：SPIESSER 研究。
Am J Transplant. 2012 Jul;12(7):1801-10. doi: 10.1111/j.1600-6143.2012.04036.x. Epub 2012 Apr 5.
5
Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation.依维莫司联合早期他克莫司最小化方案：肾移植的 III 期、随机、开放标签、多中心试验。
Transpl Int. 2012 May;25(5):592-602. doi: 10.1111/j.1432-2277.2012.01465.x. Epub 2012 Mar 26.
6
Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation.在一项肾移植后比较依维莫司与环孢素的队列研究中供体特异性 HLA 抗体。
Am J Transplant. 2012 May;12(5):1192-8. doi: 10.1111/j.1600-6143.2011.03961.x. Epub 2012 Feb 2.
7
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.了解肾移植失败的原因：抗体介导的排斥反应和不遵医行为的主导作用。
Am J Transplant. 2012 Feb;12(2):388-99. doi: 10.1111/j.1600-6143.2011.03840.x. Epub 2011 Nov 14.
8
The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients.ORION 研究：两种西罗莫司方案与他克莫司和霉酚酸酯在肾移植受者中的比较。
Am J Transplant. 2011 Aug;11(8):1633-44. doi: 10.1111/j.1600-6143.2011.03573.x. Epub 2011 Jun 10.
9
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.依维莫司为基础、不含钙调磷酸酶抑制剂的方案治疗肾移植受者：一项开放标签、随机对照试验。
Lancet. 2011 Mar 5;377(9768):837-47. doi: 10.1016/S0140-6736(10)62318-5. Epub 2011 Feb 19.
10
Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial.霉酚酸酯联合西罗莫司免疫抑制方案在肾移植中的应用：一项随机对照 sparing-the-nephron 试验。
Kidney Int. 2011 Apr;79(8):897-907. doi: 10.1038/ki.2010.492. Epub 2010 Dec 29.
Zotero 插件